Combined 18F-FDG and fluoride approach in PET/CT imaging: Is there a clinical future? [2]

Journal of Nuclear Medicine

Volumn 51, Issue 1, 2010, Pages 165-166

  Bailey, Dale L ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINE 18; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; FLUORINE; RADIOPHARMACEUTICAL AGENT;

COMPUTER ASSISTED TOMOGRAPHY; LETTER; MEDICAL RESEARCH; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; SOFT TISSUE; HUMAN; METHODOLOGY; NEOPLASM; NOTE; SCINTISCANNING; SKELETAL MUSCLE;

FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MUSCLE, SKELETAL; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 75149180970     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.066910     Document Type: Letter

References (4)

1. 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. J Nucl Med. 2009;50:501-505.
2. 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998;16:3375-3379.
3. 18F-fluorodeoxyglucose positron emission tomography. Q J Nucl Med. 2001;45:47-52.
4. Cook GJR, Fogelman I. PET imaging of the skeleton. In: Valk PE, Bailey DL, Townsend DW, Maisey MN, eds. Positron Emission Tomography: Basic Science and Clinical Practice. London, U.K.: Springer-Verlag; 2003:679-687.